Research programme: glucose responsive insulin - Protomer Technologies

Drug Profile

Research programme: glucose responsive insulin - Protomer Technologies

Latest Information Update: 04 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protomer Technologies
  • Class
  • Mechanism of Action Insulin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Type 1 diabetes mellitus

Most Recent Events

  • 25 Feb 2015 JDRF and Sanofi provide up to $4.6 million to Protomer Technologies, Monash University, North Carolina State University and University of Utah to finance development of glucose responsive insulins for Type-1 diabetes mellitus
  • 25 Feb 2015 Early research in Type-1 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top